Specific humoral immunity after single immunization with mumps vaccine: data of a 3-year follow-up


Cite item

Full Text

Abstract

The level and spectrum of humoral specific immunity were studied in 60 volunteers immunized with Russian mumps vaccine. Specific IgG levels were measured by enzyme immunoassay (EIA) and neutralization test using the Leningrad-3 (L-3) mumps virus (MV) vaccine strain and 5 heterologous MV strains of various genotypes (A, B, C, D, and H). The maximum functional activity of antibodies was recorded at an average of 18 months postvaccination. Within 3 years after vaccination, starting at 6 months, specific IgG neutralized all 6 MV strains having varying activity in relation to the genotype. Neutralizing titers (NT) against the L-3 strain were 1.3-1.7-fold higher than those against heterologous MV strains throughout the follow-up. Despite a tendency towards lower specific IgG levels, within 3 years postvaccination, EIA IgG titers remained to be 2.5 -log, L-3 strain HT were -log2 or more, and the titers against 5 heterologous MV strains were 2 -log2 or more in all the volunteers.

References

  1. Atrasheuskaya A. V., Neverov A. A., Rubin S. S., Ignatyev G. M. Horizontal transmission of the L-3 live attenuated mumps vaccine virus // Vaccine. - 2006. - Vol. 24. - P. 1530-1536.
  2. Atrasheuskaya A. V., Blatun E. M., Kulak M. V. et al. Investigation of mumps vaccine failures in Minsk, Belarus // Vaccine. - 2007. - Vol. 25. - P. 4651-4658.
  3. Atrasheuskaya A. V., Kulak M. V., Rubin S., Ignatyev G. M. Mumps vaccine failure investigation in Novosibirsk, Russia, 2002-2004 // Clin. Microbiol. Infect. - 2007. - Vol. 13. - P. 670-676.
  4. Date A. A., Kyaw M. H., Rue A. M. et al. Long-term persistence of mumps antibody after receipt of 2 MMR vaccinations and antibody response after a third MMR vaccination among a university population // J. Infect. Dis. - 2008. - Vol. 197. - P. 1662-1668.
  5. Davidkin I., Jokinen S., Broman M. et al. Persistence of measles, mumps and rubella antibodies in an MMR-vaccinated cohort: a 20-year follow up // J. Infect. Dis. - 2008. - Vol. 197. - P. 950-956.
  6. Dayan G. H., Rubin S. Mumps outbreaks in vaccinated populations; are available mumps vaccine effective enough to prevent outbreaks? // Clin. Infect. Dis. - 2008. - Vol. 47. - P. 1458- 1467.
  7. Ennis F. A. Immunity to mumps an institutional epidemic: correlation of insusceptibility to mumps with serum plague neutralizing and hemagglutination-inhibiting antibodies // J. Infect. Dis. - 1969. - P. 323-329.
  8. Hanna-Wakima R., Yasukawa L. L., Sung P. et al. Immune responses to mumps vaccine in adults who were vaccinated in childhood // J. Infect. Dis. - 2008. - Vol. 197, N 12. - P. 1669-1675.
  9. Ivancic-Jelecki J., Santak M., Forcic D. Variability of hemagglutinin-neuraminidase and nucleocapsid protein of vaccine and wild-type mumps virus strains // Infect., Genet., Evol. - 2008. - Vol. 8, N 5. - P. 603-613.
  10. Jokinen S., Osteriund P., Julkunen I., Davidkin I. Cellular immunity to mumps virus in young adults 21 years after measles-mumps-rubella vaccination // J. Infect. Dis. - 2007. - Vol. 196, N 6. - P. 861-867.
  11. Narita M., Matsuzono Y., Takekoshi Y. et al. Analysis of mumps vaccine failure by means of avidity testing for mumps virus-specific immunoglobulin G // Clin. Diagn. Lab. Immunol. - 1998. - Vol. 5, N 6. - P. 799-803.
  12. Nöjd J., Tecle T., Samuelsson A., Orvell C. Mumps virus neutralizing antibodies do not protect against reinfection with a heterologous mumps virus genotype// Vaccine. - 2001. - Vol. 19. - P. 1727-1731.
  13. Norman G. R., Streiner D. L. Biostatistics. The bare essentials. - 2-nd Ed. - London, 2000. - P. 324.
  14. Orvell C., Alsheikhly A.-R., Kalantari M., Johansson B. Characterization of genotype-specific epitopes of the HN protein of mumps virus // J. Gen. Virol. - 1997. - Vol. 8. - P. 3187- 3193.
  15. Paunio M., Hedman K., Davidkin I., Peltola H. IgG avidity to distinguish secondary from primary measles vaccination failures: prospects for a more effective global measles elimination strategy // Expert Opin. Pharmacother. - 2003. - Vol. 4, N 8. - P. 1215-1225.
  16. Peltola H., Kulkarni P. S., Kapre S. V. et al. Mumps outbreaks in Canada and the United States: time for new thinking on mumps vaccines // Clin. Infect. Dis. - 2007. - Vol. 45. - P. 459-466.
  17. Pipkin P. A., Afzal M. A., Heath A. B. et al. Assay of humoral immunity to mumps virus // J. Virol. Meth. - 1999. - Vol. 79. - P. 219-225.
  18. Rubin S., Mauldin J., Chumakov K. et al. Serological and phylogenetic evidence of monotypic immune responses to different mumps virus strains // Vaccine. - 2006. - Vol. 24. - P. 2662-2668.
  19. Rubin S. A., Qi L., Audet S. A. et al. Antibody induced by immunization with the Jeryl Lynn mumps vaccine strain effectively neutralizes a heterologous wild-type mumps virus associated with a large outbreak // J. Infect. Dis. - 2008. - Vol. 198, N 4. - P. 508-515.
  20. WHO-recommended standards for surveillance of selected vaccine-preventable diseases // Vaccines and Biologicals. - Geneva, 2003. - P. 18-20.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2011 Otrashevskaya E.V., Bukin E.K., Krasil'nikov I.V., Ignat'ev G.M., Atrasheuskaya A.V., Bukin E.K., Krasilnikov I.V., Ignatyev G.M.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС77-77676 от 29.01.2020.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies